Ratings by William Blair (Andy Hsieh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Market Perform (Outperform) |
10.64 (21.23) |
99.53% | Details | |
| 12/26/2023 | RayzeBio | RYZB | Downgrade | Market Perform (Outperform) |
30.57 (62.49) |
104.42% | Details | |
| 12/12/2023 | Icosavax Inc. | ICVX | Downgrade | Market Perform (Outperform) |
10.49 (15.31) |
45.95% | Details | |
| 11/30/2023 | Immunogen Inc. | IMGN | Downgrade | Market Perform (Outperform) |
16.06 (31.25) |
94.58% | Details | |
| 10/6/2023 | RayzeBio | RYZB | New Coverage | Outperform (N/A) |
20.06 (62.49) |
211.52% | Details | |
| 10/4/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Market Perform (Outperform) |
6.68 (12.50) |
87.13% | Details | |
| 8/3/2023 | Aravive Inc. | ARAV | Downgrade | Market Perform (Outperform) |
1.31 (0.04) |
-96.95% | Details | |
| 6/26/2023 | FibroGen | FGEN | Downgrade | Market Perform (Outperform) |
16.05 (1.13) |
-92.96% | Details | |
| 2/21/2023 | Actinium Pharma | ATNM | Downgrade | Market Perform (Outperform) |
13.76 (6.66) |
-51.6% | Details | |
| 1/31/2023 | FibroGen | FGEN | Upgrade | Outperform (Market Perform) |
21.75 (1.13) |
-94.8% | Details | |
| 7/26/2022 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2022 | Fusion Pharmaceuticals | FUSN | New Coverage | Outperform (N/A) |
2.46 (21.23) |
763.01% | Details | |
| 7/6/2022 | POINT Biopharma Global Inc. | PNT | New Coverage | Outperform (N/A) |
7.78 (12.50) |
60.67% | Details | |
| 3/14/2022 | Nektar Therapeutics | NKTR | Downgrade | Market Perform (Outperform) |
10.63 (1.28) |
-87.96% | Details | |
| 8/23/2021 | Icosavax Inc. | ICVX | New Coverage | Outperform (N/A) |
34.09 (15.31) |
-55.09% | Details | |
| 9/18/2020 | Aravive Inc. | ARAv | New Coverage | Outperform (N/A) |
5.81 (0.04) |
-99.31% | Details | |
| 8/14/2020 | Pfenex Inc. | PFNX | Downgrade | Market Perform (Outperform) |
12.89 (12.75) |
-1.09% | Details | |
| 8/8/2019 | Actinium Pharma | ATNM | New Coverage | Outperform (N/A) |
0.21 (6.66) |
3071.43% | Details | |
| 6/21/2019 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2019 | FibroGen | FGEN | Downgrade | Market Perform (Outperform) |
46.41 (1.13) |
-97.57% | Details | |
| 4/1/2019 | Celgene | CELG | Downgrade | Market Perform (Outperform) |
94.34 (108.24) |
14.73% | Details | |
| 3/12/2019 | Pfenex Inc. | PFNX | Maintain | Outperform (N/A) |
|
Details |
